TAK - Why Is Japanese Drugmaker Takeda Stock Trading Lower Today? | Benzinga
Thursday, Takeda Pharmaceutical Co Ltd (NYSE:TAK) reported a third-quarter 2023 core net profit of ¥235.9 billion, down 9.4% and 9.5% on constant currency.
Takeda’s CFO, Costa Saroukos, commented, “We remain on track towards our full-year Management Guidance at CER, reflecting significant generic impact, lower coronavirus vaccines revenue, and investment in R&D and data, digital and technology to secure our long-term competitiveness, as well as continued strong momentum in our Growth & Launch Products.”
The company reported third-quarter sales of ¥1.11 trillion, up 1.3% at the actual exchange rate (AER) and down 2.6% at the constant exchange rate (CER).
Core operating profit came in at ¥ 276.8 billion, down 16% ...